DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats

Oncogene

Volumn 32, Issue 38, 2013, Pages 4565-4571

  Yan, H X ^a,b   Wu, H P ^a,b   Zhang, H L ^b   Ashton, C ^a   Tong, C ^a   Wu, J ^a   Qian, Q J ^b   Wang, H Y ^b   Ying, Q L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

cirrhosis; DNA damage; hepatocellular carcinoma; inflammation; p53

Indexed keywords

CARBON TETRACHLORIDE; DIETHYLNITROSAMINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; GENE ACTIVATION; HEPATITIS; HOMOLOGOUS RECOMBINATION; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; SENESCENCE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; INFLAMMATION; LIVER NEOPLASMS; MALE; RATS; RATS, TRANSGENIC; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 84884586654     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.451     Document Type: Article

References (22)

1. van Veelen W, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER et al. Beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011; 60: 1204-1212.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
4. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-551.
5. Fausto N. Mouse liver tumorigenesis: Models, mechanisms, and relevance to human disease. Semin Liver Dis 1999; 19: 243-252.
6. Levine AJ, Oren M. The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
7. Livni N, Eid A, Ilan Y, Rivkind A, Rosenmann E, Blendis LM et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995; 75: 2420-2426.
8. Sarfraz S, Hamid S, Siddiqui A, Hussain S, Pervez S, Alexander G. Altered expression of cell cycle and apoptotic proteins in chronic hepatitis C virus infection. BMC Microbiol 2008; 8: 133.
9. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R et al. Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas. Cancer Res 1997; 57: 426-432.
10. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011; 121: 3343-3356.
11. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134: 657-667.
12. Abbott A. Laboratory animals: The Renaissance rat. Nature 2004; 428: 464-466.
13. Tong C, Li P, Wu NL, Yan Y, Ying QL. Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. Nature 2010; 467: 211-213.
14. Rajewsky MF, Dauber W, Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 1966; 152: 83-85.
15. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57-81.
16. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
17. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-687.
18. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008; 48: 858-879.
19. Kemp CJ. Hepatocarcinogenesis in p53-deficient mice. Mol Carcinog 1995; 12: 132-136.
20. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and deathinduced inflammation. Immunity 2011; 35: 467-477.
21. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74: 813-822.
22. van Gijssel HE, Maassen CB, Mulder GJ, Meerman JH. p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion. Carcinogenesis 1997; 18: 1027-1033.